FEMASYS INC. 10-K Summary
Business Context and Reporting Period
Company: Femasys Inc. (NASDAQ: FEMY)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Femasys is a biomedical innovator focused on women's reproductive health, specifically infertility treatment and permanent birth control. The company operates as a single business segment. Key products include FemaSeed (FDA-cleared intratubal insemination), FemVue (companion diagnostic), and FemBloc (non-surgical permanent birth control). While FemaSeed is commercially available in the U.S. and internationally, FemBloc has received CE mark certification in the EU, UK, and New Zealand but is currently in the final phase of its pivotal U.S. clinical trial (FINALE), with enrollment initiated in March 2026.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Sales | $2,293,313 | $1,629,108 |
| Cost of Sales | $872,400 | $544,903 |
| Gross Profit | $1,420,913 | $1,084,205 |
| Net Loss | $(18,627,887) | $(18,816,628) |
| Cash and Cash Equivalents (Year End) | $9,266,353 | $3,451,761 |
| Accumulated Deficit | $(145,826,144) | $(127,198,257) |
| Convertible Notes Payable (Net) | $3,178,864 | $5,406,228 |
Liquidity: As of December 31, 2025, the company held approximately $9.3 million in cash. Management estimates current resources are sufficient to fund operations into the third quarter of 2026. However, the filing explicitly states there is substantial doubt about the company's ability to continue as a going concern without additional financing.
Material Changes vs. Prior Period
- Revenue Growth: Sales increased 40.8% to $2.3 million, driven primarily by the commercialization of FemBloc in international markets (approx. $810,000 in sales) and growth in FemaSeed.
- Operating Expenses: Total operating expenses remained relatively flat (up 0.7% to $19.0 million). Research and Development (R&D) expenses decreased 7.8% due to reduced clinical costs and commercialization of development products into inventory. Sales and Marketing expenses increased 10.3% due to commercial team recruitment.
- Financing Activity: The company raised significant capital in 2025, including a $12 million senior secured convertible note issuance in November 2025, an August 2025 equity financing (approx. $7.1 million net), and a June 2025 offering. This resulted in a net cash inflow from financing activities of $25.1 million.
- Debt Structure: The company repaid its 2023 convertible notes in full during 2025. The new 2025 notes carry an 8.5% interest rate payable in-kind (PIK), which compounds the principal balance and potential dilution.
Guidance, Outlook, and Risks
Outlook: The company expects to continue incurring operating losses for the foreseeable future. Success depends heavily on the successful completion of the FemBloc pivotal trial and subsequent FDA approval. Management anticipates needing substantial additional funding to complete U.S. development and commercialization.
Key Risks:
- Going Concern: Substantial doubt exists regarding the ability to continue operations without raising additional capital. Current cash is insufficient to fund operations through U.S. regulatory approval of FemBloc.
- Nasdaq Compliance: The company received deficiency notices regarding Market Value of Listed Securities (MVLS) and Minimum Bid Price requirements. It has been granted a final 180-day extension until July 13, 2026, to regain compliance, potentially via a reverse stock split. Failure to comply could result in delisting.
- Dilution: The November 2025 financing included convertible notes and warrants that could result in the issuance of approximately 65.7 million shares if fully converted/exercised, representing significant dilution to existing shareholders.
- Regulatory Approval: U.S. commercialization of FemBloc is contingent on FDA approval, which is not guaranteed. Delays or failure in the pivotal trial would materially harm the business.
Investor Verification Checklist
- Cash Runway: Verify the specific timeline for cash depletion and the status of any new financing efforts post-year-end.
- Nasdaq Status: Monitor the company's progress in regaining compliance with Nasdaq listing standards by the July 13, 2026 deadline.
- Clinical Trial Progress: Track enrollment rates and interim data releases for the FemBloc FINALE pivotal trial (NCT05977751).
- Dilution Impact: Assess the potential impact of the 2025 convertible notes (PIK interest) and warrant exercises on share count and earnings per share.
- Revenue Concentration: Note that one customer (Kebomed Europe AG) accounted for 21% of 2025 revenue; monitor the stability of international distribution partnerships.